Bruton Tyrosine Kinase Inhibitor-related Atrial Fibrillation and Its Implications in the Treatment of B-cell Lymphoma

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Aug 12

PMID 39131702

Authors

Jun Du

Ze-Yu Chen

Xiao-Ran Gu

Ting Wang

Zou-Fang Huang

Affiliations

Soon will be listed here.

Abstract

Adverse events of atrial fibrillation (AF) have been commonly reported in lymphoma patients in treating Bruton's tyrosine kinase inhibitors (BTKi). The incidence rate of AF can vary depending on the specific types of BTKi and the patient population. Totally 45 published studies have revealed that the overall incidence rate of AF is 5% (95% CI 4%-7%). By performing a subtype single-rate analysis, the second-generation BTKi shows a lower AF incidence rate and lower cardiovascular toxicity. In the subtype single-rate analysis, we conclude the different AF incidence rates of Ibrutinib (10%, 95% CI 7%-13%), Acalabrutinib (4%, 95% CI 1%-6%), Orelabrutinib (0%, 95% CI 0%-1%), and Zanubrutinib (0%, 95% CI 0%-1%). The comprehensive analysis of AF inspires us to better predict and manage AF and other cardiovascular events in treating lymphoma. Meticulous evaluation, collaboration between cardiologists and hematologists, and discovery of new biomarkers are essential for its management.

References

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G . Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019; 380(22):2095-2103. PMC: 11827445. DOI: 10.1056/NEJMoa1900574. View

Castillo J, Meid K, Gustine J, Leventoff C, White T, Flynn C . Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2021; 36(2):532-539. PMC: 8807393. DOI: 10.1038/s41375-021-01417-9. View

Furman R, Byrd J, Owen R, OBrien S, Brown J, Hillmen P . Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia. 2021; 35(11):3201-3211. DOI: 10.1038/s41375-021-01252-y. View

Strati P, Coleman M, Champion R, Ma S, Patti C, Levy M . A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Br J Haematol. 2022; 199(1):76-85. PMC: 9796553. DOI: 10.1111/bjh.18368. View

Trotman J, Buske C, Tedeschi A, Matous J, MacDonald D, Tam C . Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate Trial. Clin Cancer Res. 2021; 27(21):5793-5800. PMC: 9401517. DOI: 10.1158/1078-0432.CCR-21-1497. View

Burger J . Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer J. 2019; 25(6):386-393. PMC: 7083517. DOI: 10.1097/PPO.0000000000000412. View

Byrd J, Brown J, OBrien S, Barrientos J, Kay N, Reddy N . Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3):213-23. PMC: 4134521. DOI: 10.1056/NEJMoa1400376. View

Tam C, Opat S, DSa S, Jurczak W, Lee H, Cull G . A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020; 136(18):2038-2050. PMC: 7596850. DOI: 10.1182/blood.2020006844. View

Byrd J, Hillmen P, Ghia P, Kater A, Chanan-Khan A, Furman R . Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021; 39(31):3441-3452. PMC: 8547923. DOI: 10.1200/JCO.21.01210. View

10.

Oikonomou E, Zografos T, Papamikroulis G, Siasos G, Vogiatzi G, Theofilis P . Biomarkers in Atrial Fibrillation and Heart Failure. Curr Med Chem. 2017; 26(5):873-887. DOI: 10.2174/0929867324666170830100424. View

11.

Jain P, Zhao S, Lee H, Hill H, Ok C, Kanagal-Shamanna R . Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2021; 40(2):202-212. PMC: 8718245. DOI: 10.1200/JCO.21.01797. View

12.

Treon S, Tripsas C, Meid K, Warren D, Varma G, Green R . Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015; 372(15):1430-40. DOI: 10.1056/NEJMoa1501548. View

13.

Sharman J, Egyed M, Jurczak W, Skarbnik A, Pagel J, Flinn I . Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020; 395(10232):1278-1291. PMC: 8151619. DOI: 10.1016/S0140-6736(20)30262-2. View

14.

Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Santucci Silva R, Grosicki S . Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2015; 17(2):200-211. DOI: 10.1016/S1470-2045(15)00465-9. View

15.

Sestier M, Hillis C, Fraser G, Leong D . Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation. Curr Oncol Rep. 2021; 23(10):113. PMC: 8330192. DOI: 10.1007/s11912-021-01102-1. View

16.

Wang M, Rule S, Zinzani P, Goy A, Casasnovas O, Smith S . Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2017; 391(10121):659-667. PMC: 7864374. DOI: 10.1016/S0140-6736(17)33108-2. View

17.

Tam C, Trotman J, Opat S, Burger J, Cull G, Gottlieb D . Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019; 134(11):851-859. PMC: 6742923. DOI: 10.1182/blood.2019001160. View

18.

Wang M, Rule S, Martin P, Goy A, Auer R, Kahl B . Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-16. PMC: 4513941. DOI: 10.1056/NEJMoa1306220. View

19.

Burger J, Tedeschi A, Barr P, Robak T, Owen C, Ghia P . Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 373(25):2425-37. PMC: 4722809. DOI: 10.1056/NEJMoa1509388. View

20.

Zimetbaum P . Atrial Fibrillation. Ann Intern Med. 2017; 166(5):ITC33-ITC48. DOI: 10.7326/AITC201703070. View